WMWitsarut Manasirisuk

Witsarut Manasirisuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Witsarut Manasirisuk has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy of Standard Triple Therapy With or Without Statin in Helicobacter pylori Eradication: A Randomized Double‐Blind Placebo‐Controlled Trial

    by Chitchai Rattananukrom, Punnaphol Waranophirun, Anupol Panitchote, Suda Vannaprasaht, Tanita Suttichaimongkol, Kookwan Sawadpanich, Apichart Sangchan, Wattana Sukeepaisarnjaroen, Pisaln Mairiang, Witsarut Manasirisuk

    Background and Aims: Standard triple therapy (STT) for Helicobacter pylori ( H. pylori ) infection has become suboptimal. Atorvastatin may improve eradication rates by promoting autophagy and reducing inflammation. This study aimed to evaluate the efficacy and safety of adjuvant atorvastatin with STT compared to STT alone for H. pylori eradication. Methods: In this randomized, placebo‐controlled trial, 138 treatment‐naïve patients with H. pylori infection were randomized to two groups. The intervention group ( n = 70) received a 14‐day regimen of omeprazole, amoxicillin, clarithromycin, and atorvastatin (40 mg once daily). The control group ( n = 68) received the same regimen with a matching placebo. The primary endpoint was H. pylori eradication, assessed by a urea breath test 4–6 weeks after treatment completion. Secondary endpoints included CYP2C19 and CYP3A4/5 genotypes, adverse events, and patient compliance. Results: The eradication rate in the intervention group was significantly higher than in the control group in both the per‐protocol (97.1% vs. 85.3%) and intention‐to‐treat (ITT) analyses (95.7% vs. 85.3%). The absolute risk difference for the ITT analysis was 10.4% (95% CI, 0.75 to 20.1; p = 0.03). The distribution of CYP2C19 and CYP3A4/5 genotypes was similar between groups. No clinically significant differences in adverse events were observed. Conclusion: Adjuvant therapy with atorvastatin combined with STT significantly improved H. pylori eradication rates without clinically significant adverse events. Further randomized controlled trials in diverse populations and with varying antibiotic resistance patterns are needed to better clarify the effects of statins on H. pylori treatment. Trial Registration: Thai Clinical Trial Registry, No. TCTR20220201001

  • Overall Survival and Treatment Outcomes in Patients With Primary Biliary Cholangitis: A 10-Year Single-Center Retrospective Cohort Study

    by Shunyapat Sirirattanakorn, Tanita Suttichaimongkol, Witsarut Manasirisuk, Kookwan Sawadpanich, Apichart Sangchan, Pisaln Mairiang, Wattana Sukeepaisarnjareon, Chitchai Rattananukrom


  • Open Access

    Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial

    by Grace Lai-Hung Wong, Man-Fung Yuen, Bingliang Lin, Mark W. Douglas, Peng Hu, Qing Xie, Fangfang Lv, Won Young Tak, Apinya Leerapun, Dong Joon Kim, et al.

    Functional cure is a goal for the treatment of chronic hepatitis B virus (HBV) infection; however, it is infrequently achieved with currently approved treatments. Here we provide a randomized evaluation of the small interfering RNA elebsiran, in combination with pegylated interferon alfa (PEG-IFNα), compared with PEG-IFNα monotherapy. In addition, this study evaluates the potential role of the HBV therapeutic vaccine BRII-179 in identifying immunologically responsive patients and improving hepatitis B surface antigen (HBsAg) loss rates. In part I (cohorts 1–3), virally suppressed participants with chronic HBV infection naive to BRII-179 were randomized 1:1:1 to receive 48 weekly doses of PEG-IFNα alone or in combination with 13 doses of elebsiran (200 mg or 100 mg) administered every 4 weeks. In part II (cohort 4), participants who had previously received 9 doses of elebsiran and BRII-179 in a prospective study (BRII-179-835-001) were categorized as BRII-179 anti-HBs responders or nonresponders based on their peak hepatitis B surface antibody (anti-HBs) levels (≥10 IU l−1 or −1, respectively) and subsequently received 13 doses of elebsiran 100 mg every 4 weeks plus 48 weekly doses of PEG-IFNα. Primary endpoints were HBsAg loss at the end of treatment (EOT) and 24 weeks post-EOT. In part I, at 24 weeks post-EOT, HBsAg loss was observed in 4 out of 19 (21.1%) participants receiving elebsiran 200 mg plus PEG-IFNα, 6 out of 18 (33.3%) participants receiving elebsiran 100 mg plus PEG-IFNα and 1 out of 18 (5.6%) participants receiving PEG-IFNα monotherapy. In part II, HBsAg loss was observed in 9 out of 31 (29.0%) participants at 24 weeks post-EOT, with a higher response among BRII-179 anti-HBs responders (8 out of 19 participants, 42.1%) compared with nonresponders (1 out of 12 participants, 8.3%). Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated. These results demonstrate an additive benefit of elebsiran when combined with PEG-IFNα in achieving sustained HBsAg loss. Furthermore, the increased HBsAg loss rate in BRII-179 anti-HBs responders suggests that BRII-179 may be a valuable tool for immunological profiling to optimize curative outcomes in patients with HBV infection. ClinicalTrials.gov registration: NCT05970289.


  • One vs Five Days of Octreotide Infusion for Acute Esophageal Variceal Bleeding: A Randomized Controlled Trial

    by Sakkarin Chirapongsathorn, Arunchai Chang, Suppakorn Malikhao, Dhanusorn Wanichagool, Witsarut Manasirisuk, Uayporn Kaosombatwattana, Attapon Rattanasupar, Nuttida Polpanich, Phadet Noophun, Anuchit Suksamai, et al.

    INTRODUCTION: The optimal duration of octreotide infusion for esophageal variceal bleeding remains unclear. We aimed to compare the efficacy of 1-day vs 5-day octreotide infusion combined with endoscopic therapy, with the primary outcome of early (5-day) rebleeding under a noninferiority framework and secondary outcomes of 6-week rebleeding and all-cause mortality. METHODS: This nationwide, multicenter, noninferiority, open-label, randomized, controlled trial included 220 patients with cirrhosis and acute esophageal variceal bleeding who underwent endoscopic band ligation in 5 tertiary-care and 3 university-based hospitals across Thailand. They received a 1-day (n = 109) or 5-day (n = 111) regimen of continuous octreotide infusion after successful endoscopy. Rebleeding, transfusion requirements, and mortality were assessed. RESULTS: Most participants were men (180/220), and the average age was 56 years. The 5-day rebleeding (1.83% vs 1.80%, P ≥ 0.99), 6-week rebleeding (8.26% vs 10.81%, P = 0.52), and 6-week all-cause mortality (5.50% vs 6.31%, P = 0.80) rates were similar between the 1-day and 5-day groups. The event-rate difference in early rebleeding was 0.03%, indicating noninferiority (95% CI, 3.50%–3.56%). Patients in the 1-day group required significantly fewer blood transfusions and had a shorter time to oral diet and shorter hospital stay. DISCUSSION: After successful endoscopic band ligation, the 1-day regimen of octreotide had a noninferior effect compared with the standard 5-day regimen in the prevention of 5-day rebleeding and exhibited no significant differences in the prevention of 6-week rebleeding and all-cause mortality. Trial registration number: Thai Clinical Trials Registry, TCTR 20221004008.